Deutsch English Français

Contact

EP2694496

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2694496

EP2694496 - 3- OR 5-BIPHENYL-4-YLISOXAZOLE-BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN , CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS [Right-click to bookmark this link]
Former [2014/07]	3- OR 5 - BI PHENYL - 4 - YLISOXAZOLE - BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN, CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS
	[2017/27]
Status	The application is deemed to be withdrawn Status updated on 27.04.2018 Database last updated on 11.09.2024
Former	Grant of patent is intended Status updated on 17.07.2017
Most recent event Tooltip	27.04.2018	Application deemed to be withdrawn	published on 30.05.2018 [2018/22]
Applicant(s)	For all designated states Amira Pharmaceuticals, Inc. Route 206 & Province Line Road Princeton, NJ 08543 / US
	[2014/07]
Inventor(s)	01 / SEIDERS, Thomas, Jon 5257 Soledad Mountain Road San Diego, CA 92109 / US
	02 / ROPPE, Jeffrey, Roger 45004 Oakford Ct Temecula, CA 92592 / US
	03 / PARR, Timothy, Andrew 8504 Lemon Avenue La Mesa, CA 91941 / US
	[2014/19]
Former [2014/07]	01 / SEIDERS, Thomas, Jon 5257 Soledad Mountain Road San Diego, CA 92109 / US
	02 / ROPPE, Jeffrey, Roger 32182 Camino Guarda Temecula, CA 92592 / US
	03 / PARR, Timothy, Andrew 8504 Lemon Avenue La Mesa, CA 91941 / US
Representative(s)	Reitstötter Kinzebach Patentanwälte Sternwartstraße 4 81679 München / DE
	[N/P]
Former [2014/07]	Reitstötter - Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
Application number, filing date	12718774.8	04.04.2012
	WO2012US32222
Priority number, date	US201161472100P	05.04.2011 Original published format: US 201161472100 P
	[2014/07]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2012138797
	Date:	11.10.2012
	Language:	EN
	[2012/41]
	Type:	A1 Application with search report
	No.:	EP2694496
	Date:	12.02.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.10.2012 takes the place of the publication of the European patent application.
	[2014/07]
Search report(s)	International search report - published on:	EP	11.10.2012
Classification	IPC:	C07D413/12, A61K31/4439, A61P9/10, A61P11/06, A61P17/02, A61P25/00, A61P35/00, A61P37/08	[2014/07]
	CPC:	C07D413/12 (EP,CN,US); A61P1/00 (EP); A61P1/16 (EP); A61P11/00 (EP); A61P11/06 (EP); A61P13/12 (EP); (+) A61P17/00 (EP); A61P17/02 (EP); A61P25/00 (EP); A61P25/04 (EP); A61P27/02 (EP); A61P29/00 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP); A61P37/06 (EP); A61P37/08 (EP); A61P9/00 (EP); A61P9/10 (EP) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/07]
Title	German:	ZUR BEHANDLUNG VON FIBROSE, SCHMERZEN, KREBS, ALLERGIEN UND ERKRANKUNGEN DER ATEMWEGE, DES NERVENSYSTEMS ODER DES HERZKREISLAUFSYSTEMS GEEIGNETE AUF 3- ODER 5-BIPHENYL-4-YLISOXAZOL BASIERENDE VERBINDUNGEN	[2017/31]
	English:	3- OR 5-BIPHENYL-4-YLISOXAZOLE-BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN , CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS	[2017/27]
	French:	COMPOSES A BASE DE 3- OU 5-BIPHENYL-4-YLISOXAZOLE UTILES POUR LE TRAITEMENT DE LA FIBROSE, DE LA DOULEUR, DU CANCER, DE TROUBLES RESPIRATOIRES OU DU SYSTEME NERVEUX CENTRAL ET DE MALADIES ALLERGIQUES OU CARDIOVASCULAIRES	[2017/31]
	Former [2014/07]	3-ODER 5 - BIPHENYL- 4 - YLISOXAZOL -BASIERTE VERBINDUNGEN ZUR BEHANDLUNG VON FIBROSE, SCHMERZEN, KREBS, ATEMWEGSERKRANKUNGEN, ALLERGIEN, DES NERVENSYSTEMS ODER VON KARDIOVASKULÄREN ERKRANKUNGEN
	Former [2014/07]	3- OR 5 - BI PHENYL - 4 - YLISOXAZOLE - BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN, CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS
	Former [2014/07]	COMPOSÉS À BASE DE 3- OU 5-BIPHÉNYL-4-YLISOXAZOLE UTILES POUR LE TRAITEMENT DE LA FIBROSE, DE LA DOULEUR, DU CANCER ET DE TROUBLES RESPIRATOIRES, ALLERGIQUES, DE TROUBLES DU SYSTÈME NERVEUX OU DE TROUBLES CARDIOVASCULAIRES
Entry into regional phase	19.09.2013	National basic fee paid
	19.09.2013	Designation fee(s) paid
	19.09.2013	Examination fee paid
Examination procedure	19.09.2013	Examination requested [2014/07]
	22.05.2014	Amendment by applicant (claims and/or description)
	18.07.2017	Communication of intention to grant the patent
	29.11.2017	Application deemed to be withdrawn, date of legal effect [2018/22]
	09.01.2018	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2018/22]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 18.07.2017
Fees paid	Renewal fee
	25.03.2014	Renewal fee patent year 03
	10.04.2015	Renewal fee patent year 04
	11.04.2016	Renewal fee patent year 05
	10.04.2017	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[AD]US2007225285 (HUTCHINSON JOHN H [US], et al) [AD] 1-15 * page 1, paragraph 9 * * page 149 - page 150; table 5 *
	by applicant	WO02062389
		US4229447
		US4596795
		US4755386
		US5739136
		US7060697
		EP0079157
		US2007225285
		US2007219206
		US2007173508
		US2007123522
		US2007105866
		US2007149579
		WO2007016784
		- CHOI ET AL., BIOCHEMICA ET BIOPHYSICA ACTA, (2008), vol. 1781, pages 531 - 539
		- MILLS ET AL., NAT REV. CANCER, (2003), vol. 3, pages 582 - 591
		- J.P. PRADCRC ET AL., "LPA, receptor activation promotes renal interstitial fibrosis", J. AM. SOC. NEPHROL., (2007), vol. 18, doi:doi:10.1681/ASN.2007020196, pages 3110 - 3118, XP002682319 DOI: http://dx.doi.org/10.1681/ASN.2007020196
		- N. WIEDMAIER ET AL., INTJMED MICROBIOL, (2008), vol. 298, no. 3-4, pages 231 - 43
		- A. KANTARCI ET AL., J. PATHOL., (2006), vol. 210, pages 59 - 66
		- N. WATANABE ET AL., "Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity", LIFE SCI., (2007), vol. 81, doi:doi:10.1016/j.lfs.2007.08.013, pages 1009 - 1015, XP022248228 DOI: http://dx.doi.org/10.1016/j.lfs.2007.08.013
		- N.WATANABE ET AL., J. CLIN. GASTROENTEROL., (2007), vol. 41, pages 616 - 623
		- K. KURODA ET AL., "Phospholipid concentration in lung lavage fluid as biomarker for pulmonary fibrosis", INHAL. TOXICOL., (2006), vol. 18, pages 389 - 393
		- K. YASUDA ET AL., LUNG, (1994), vol. 172, pages 91 - 102
		- CHEN ET AL., FEBS LETT., (20060821), vol. 580, no. 19, pages 4737 - 45
		- TAGER ET AL., NATURE MEDICINE, (2008), vol. 14, no. 1, pages 45 - 54
		- MUNGER ET AL., CELL, (1999), vol. 96, pages 319 - 328
		- XU ET AL., AM. J. PATHOLOGY, (2009), vol. 174, no. 2, pages 1264 - 1279
		- C.N. INOUE ET AL., CLIN. SCI. (COLCH., (1999), vol. 96, pages 431 - 436
		- J.S. KOH, J CLIN. INVEST., (1998), vol. 102, pages 716 - 727
		- M. INOUE ET AL., "Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling", NAT. MED., (2004), vol. 10, doi:doi:10.1038/nm1060, pages 712 - 718, XP002693859 DOI: http://dx.doi.org/10.1038/nm1060
		- MOL CANCER THER, (2008), vol. 7, no. 10, pages 3352 - 62
		- GARDELL ET AL., TRENDS IN MOLECULAR MEDICINE, (2006), vol. 12, no. 2, pages 65 - 75
		- ISHII ET AL., ANNU. REV. BIOCHEM, (2004), vol. 73, pages 321 - 354
		- MILLS ET AL., NAT. REV. CANCER, (2003), vol. 3, pages 582 - 591
		- MURPH ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, (2008), vol. 1781, pages 547 - 557
		- YAMADA ET AL., J. BIOL. CHEM., (2004), vol. 279, pages 6595 - 6605
		- YAMADA, CANCER SCI., (2008), vol. 99, no. 8, pages 1603 - 1610
		- BOUCHARABA ET AL., J. CLIN. INVEST., (2004), vol. 114, no. 12, pages 1714 - 1725
		- BOUCHARABA ET AL., PROC. NATL. ACAD. SCI., (2006), vol. 103, no. 25, pages 9643 - 9648
		- MILLS ET AL., NAT. REV. CANCER., (2003), vol. 3, pages 582 - 591
		- SUTPHEN ET AL., CANCER EPIDEMIOL. BIOMARKERS PREV., (2004), vol. 13, pages 1185 - 1191
		- J.J.A. CONTOS ET AL., MOL. PHARMACOL., (2000), vol. 58, pages 1188 - 1196
		- M. AMISHIMA ET AL., AM. J. RESPIR. CRIT. CARE MED., (1998), vol. 157, pages 1907 - 1912
		- EDIGER ET AL., EUR RESPIR .J, (2003), vol. 21, pages 759 - 769
		- HASHIMOTO ET AL., JPHARMACOL SCI, (2006), vol. 100, pages 82 - 87
		- MOOLENAAR, CURR. OPIN. CELL BIOL., (1995), vol. 7, pages 203 - 10
		- J. NEUROCHEM., (1993), vol. 61, page 340
		- J. NEUROCHEM., (1998), vol. 70, page 66
		- ISHII, I. ET AL., ANNU. REV. BIOCHEM., (2004), vol. 73, pages 321 - 354
		- OSBORNE, N.; STAINIER, D.Y., ANNU. REV. PHYSIOL., (2003), vol. 65, pages 23 - 43
		- MAGUIRE, J.J., TRENDS PHARMACOL. SCI., (2005), vol. 26, pages 448 - 454
		- SIESS, W., BIOCHIM. BIOPHYS. ACTA, (2002), vol. 1582, pages 204 - 215
		- ROTHER, E. ET AL., CIRCULATION, (2003), vol. 108, pages 741 - 747
		- GARDELL ET AL., TRENDS IN MOLECULAR MEDICINE, (200602), vol. 12, no. 2
		- BIOCHEM BIOPHYS RES COMMUN., (2007), vol. 363, no. 4, pages 1001 - 8
		- BIOCHEM BIOPHYS RES CNMMUN., (19921215), vol. 193, no. 2, page 497
		- J. LMUUNOL., (1999), vol. 162, page 2049
		- THE JOURNAL OF UROLOGY, (1999), vol. 162, pages 1779 - 1784
		- THE JOURNAL OF UROLOGY, (2000), vol. 163, pages 1027 - 1032
		- KOTANI ET AL., HUM. MOL. GENET., (2008), vol. 17, pages 1790 - 1797
		- ZHAO ET AL., MOL. PHARMACOL., (2008), vol. 73, no. 2, pages 587 - 600
		- SIMON ET AL., J.BIOL. CHEM., (2005), vol. 280, no. 15, page 14656
		- CAREY; SUNDBERG, ADVANCED ORGANIC CHEMISTRY 4th Ed.,, PLENUM, (2000), vol. A, B
		- OZDEMIR ET AL., TETRAHEDRON, (2005), vol. 61, pages 9791 - 9798
	- ACKERMANN ET AL., ORG. LETT., (2006), vol. 8, pages 3457 - 3460
	- BLAKEY ET AL., J. AM. CHEM. SOC., (2003), vol. 125, pages 6046 - 6047
	- DAI ET AL., ORG. LETT., (2004), vol. 6, pages 221 - 224
	- YOSHIKAI ET AL., J. AM. CHEM. SOC., (2005), vol. 127, pages 17978 - 17979
	- TANG ET AL., J. ORG. CHEM., (2006), vol. 71, pages 2167 - 2169
	- MURATA ET AL., SYNTHESIS, (2001), pages 2231 - 2233
	- SINGH ET AL., Encyclopedia of Pharmaceutical Technology, 2nd Ed.,, (2002), pages 754 - 757
	- MOTOTANI ET AL., HUM. MOL. GENETICS, (2008), vol. 17, no. 12
	- TSUJI ET AL., ORG. BIOMOL. CHEM., (2003), vol. 1, pages 3139 - 3141
	- AN ET AL., BINCHEM. BINPHYS. RES. COMMUN., (1997), vol. 231, page 619
	- CUZZOCREA S ET AL., AM JPHYSIOL LUNG CELL MOL PHYSIOL., (20070112), vol. 292, no. 5, pages L1095 - 104
	- ASHCROFT T., J. CLIN. PALH., (1988), vol. 41, no. 4, pages 467 - 470
	- HIGAZI, A. A. ET AL., CLIN EXP IMMUNOL., (20080214), vol. 152, no. 1, pages 163 - 73
	- AAPS PHARMSCITECH., (2006), vol. 7, no. 2, page E41

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p